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The HTT CAG-Expansion Mutation Determines Age at Death
but Not Disease Duration in Huntington Disease
Jae Whan Keum,1 Aram Shin,1 Tammy Gillis,1 Jayalakshmi Srinidhi Mysore,1 Kawther Abu Elneel,1
Diane Lucente,1 Tiffany Hadzi,2 Peter Holmans,3,9 Lesley Jones,3,9 Michael Orth,4,9 Seung Kwak,5,9
Marcy E. MacDonald,1,6,7,9 James F. Gusella,1,7,8,9 and Jong-Min Lee1,6,7,9,*
Huntington disease (HD) is caused by an expanded HTT CAG repeat that leads in a length-dependent, completely dominant manner to
onset of a characteristic movement disorder. HD also displays early mortality, so we tested whether the expanded CAG repeat exerts a
dominant influence on age at death and on the duration of clinical disease. We found that, as with clinical onset, HD age at death is
determined by expanded CAG-repeat length and has no contribution from the normal CAG allele. Surprisingly, disease duration is in-
dependent of the mutation’s length. It is also unaffected by a strong genetic modifier of HD motor onset. These findings suggest two
parsimonious alternatives. (1) HD pathogenesis is driven by mutant huntingtin, but before or near motor onset, sufficient CAG-driven
damage occurs to permit CAG-independent processes and then lead to eventual death. In this scenario, some pathological changes and
their clinical correlates could still worsen in a CAG-driven manner after disease onset, but these CAG-related progressive changes do not
themselves determine duration. Alternatively, (2) HD pathogenesis is driven by mutant huntingtin acting in a CAG-dependent manner
with different time courses in multiple cell types, and the cellular targets that lead to motor onset and death are different and indepen-
dent. In this scenario, processes driven byHTTCAG length lead directly to death but not via the striatal pathology associated withmotor
manifestations. Each scenario has important ramifications for the design and testing of potential therapeutics, especially those aimed at
preventing or delaying characteristic motor manifestations.Introduction
Huntington disease (HD [OMIM: 143100]) is a dominantly
inherited disorder1,2 whose characteristic neurological
symptoms result from an expanded CAG repeat of greater
than 35 units in the huntingtin-encoding sequence ofHTT
(OMIM: 613004).2–5 It has long been known that the age of
onset of HDmotor symptoms is negatively correlated with
the length of the expanded HTT CAG repeat,2,6–9 but the
question of whether the length of the normal CAG allele
also plays a role in determining onset remained uncertain
until recently. Two publications reported that a complex
interaction between the CAG-repeat lengths of the normal
and expanded alleles played a significant role in deter-
mining an individual’s age at motor onset.10,11 However,
a more comprehensive study recently uncovered issues
with the statistical analysis of the correlation between
age at onset and the CAG repeat, developed a route to
robust statistical analysis of such data, and concluded
that the length of the normal CAG allele has no significant
impact, either alone or in interaction with the expanded
CAG repeat, on age at motor onset.12 Consistent with
this conclusion, age at motor onset of HD subjects with
two expanded HTT alleles is determined by the longer of
their two CAG repeats and is similar to that of subjects
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The Americthe expanded HTT CAG repeat triggers HD pathogenesis
(defined here as the underlying abnormal process that
leads to pathology, defined in turn as disease phenotype),
and the length of the mutation largely determines the
rate of the pathogenic process that leads to clinical motor
signs in a fully dominant fashion. The motor disturbances
are thought to result from dysfunction and degeneration
of neurons in the striatum, which, according to post-mor-
tem pathological examination of brains, is also correlated
with CAG-repeat length.13–16 The relationship among
CAG-repeat length, age at motor onset, and inferred rate
of striatal pathology has informed the potential for treat-
ment by HTT silencing, given that the lack of an effect of
either the normal allele or an interaction between normal
and expanded alleles implies that one can target the single
mutant copy of HTT in the striatum to delay onset and
worsening of motor symptoms.
Another important HD feature that has been reported to
show a strong correlation with expanded CAG-repeat
length is age at death.6,9,17 Compared to the general popu-
lation, HD subjects show early mortality,18 but it is not
clear whether this reflects a direct or an indirect effect of
mutant huntingtin on vital processes. In principle, early
mortality in HD could be due to neurodegenerative
changes in the regions most associated with HD clinical
symptoms or, alternatively, to some other independent, MA 02114, USA; 2GNS Healthcare Inc., One Charles Park, Cambridge, MA
cs and Genomics, Department of Psychological Medicine and Neurology,
Neurology, University of Ulm, Ulm 089081, Germany; 5CHDI Foundation,
Boston, MA 02115, USA; 7Medical and Population Genetics Program, Broad
etics, Harvard Medical School, Boston, MA 02115, USA; 9Genetic Modifiers
y of Human Genetics. All rights reserved.
an Journal of Human Genetics 98, 287–298, February 4, 2016 287
Table 1. Summary of Statistical Models for Testing Effects of CAG-Repeat Sizes on Age at Death in HD
Sample Size
Estimate (p Value)
Adjusted R2Expanded CAG Normal CAG Gender (Male)
Model 1 1,019 0.056722 (<2E16) 0.001636 (0.134840) 0.026275 (0.000288) 66.9%
Model 2 1,019 0.056723 (<2E16) not tested 0.026240 (0.000296) 66.9%
Model 3 1,165 0.0363498 (<2E16) 0.00259 (0.06007) 0.0288 (0.00157) 74.8%
Two different statistical models were constructed to test the impact of CAG repeats on age at death of HD subjects by using QC-passed data points. Natural-log-
transformed age at death was modeled as a function of expanded CAG, normal CAG, and gender with the use of QC-passed data points (model 1). After the
normal CAG was confirmed to have no effect on age at death, model 2 was constructed with only the expanded CAG repeat and gender. Finally, for evaluating
the impact of samples excluded in models 1 and 2, model 3 was fitted to data including all HD subjects with age-at-death data. Interaction between expanded and
normal CAG repeats was not significant and was therefore excluded from modeling.effect of mutant huntingtin.16,19–25 In order to inform po-
tential treatments for preventing or delaying disease onset
and early death of HD subjects, we performed a compre-
hensive statistical assessment of the impact of the
expanded and normal CAG repeats on determining the
timing of death and the relationship between this timing
and the prior onset of diagnostic motor signs, an interval
that we define as ‘‘disease duration.’’ Our findings suggest
that the expanded CAG repeat has a dominant effect on
age at death, as it does on age at motor onset, and that
the normal CAG allele has no impact. However, they also
indicate a surprising lack of contribution of either the
mutant or the normal HTT allele to the duration of clinical
disease from onset to death. We propose two alternative
explanations for the relationship between motor onset
and death and show that they have quite different implica-
tions for designing therapies in HD.Material and Methods
Study Subjects
We analyzed DNA samples from 4,448 HD heterozygous subjects
with either a known age at onset of motor signs and/or age at
death: 4,161 subjects had age-at-onset data, 1,165 subjects had
age-at-death data, and 878 subjects had both. Subjects with a re-
corded age at death were primarily identified from HD brain
banks: the Harvard Brain Tissue Resource Center (McLean Hospi-
tal, Belmont), the New York Brain Bank (Columbia University,
New York City), the National Neurological Research Specimen
Bank (Department of Veterans Affairs Medical Center, Los An-
geles), and the Harvard NeuroDiscovery Center Advanced Tissue
Resources Core (Massachusetts General Hospital, Charlestown).
HD subjects with a recorded age at onset were described previ-
ously.12 The lengths of HTT CAG repeats for each DNA sample
were determined by a PCR assay against sequenced-allele size stan-
dards as described previously.26 Primary analysis was based on HD
subjects who carried one expanded HTT CAG repeat (CAG > 35).
The means of expanded and normal CAG-repeat lengths of our
study subjects were 45.1 (range ¼ 36–120; median ¼ 44) and
18.45 (range ¼ 9–35; median ¼ 18), respectively. Age at death,
age at onset of motor signs, and disease duration (the difference
between age at onset and age at death) were the primary depen-
dent variables in the statistical models. Ages at onset were esti-
mated by a clinician rater, reported by a family member, and/or
self-reported. When multiple ages at onset were available, priority288 The American Journal of Human Genetics 98, 287–298, Februarywas given first to the expert rater’s estimate and then to the family
member’s report. In addition to analyzing ascertained subjects for
onset and/or death, we also independently analyzed observational
cohort data from the European Huntington’s Disease Network
(EHDN) Registry to construct survival models. CAG repeats of
EHDN samples were determined by the same method as above.
The familial relationships of our samples were not known because
our de-identified data lacked pedigree information. Because
related individuals tend to cause statistical inflation, the lack of
significant influence in our results would not change dramatically
if familial relationships could be included in the model. The study
was approved by the Partners HealthCare institutional review
board.Statistical Analysis of Age at Death
We previously described a robust statistical-analysis method for
age at onset of motor signs12 and used it in this study for the anal-
ysis of age at death. Natural-log-transformed age-at-death data
from 1,165 subjects were modeled as a function of (1) expanded
CAG length, (2) normal CAG length, and (3) gender (Table 1,
model 3). In addition, we performed quality-control (QC) analyses
to identify a subset of data that met the requirements of linear-
regression modeling, including (1) normality, (2) equal variance,
and (3) absence of disproportionately influential observations.
First, we evaluated data normality for each CAG-repeat length
and found that the distribution of age at death approximated a
normal distribution for subjects with 40–52 CAG repeats, repre-
senting 90.3% of the samples (Figure S1). Variance in age at death
was not constant but rather was larger for subjects with smaller
expanded CAG repeats, potentially implicating a greater role for
modifiers in this range (Figure S2A). We addressed the non-con-
stant variance by log transformation of the data (as shown in
Figure S2B), which also rendered the relationship between
expanded CAG-repeat length and age at death close to linear
(Figure S2C). Lastly, we identified which outliers to exclude by us-
ing a standard interquartile-outlier-identification method (Fig-
ure S2C). In brief, for each CAG-repeat size, we sorted age-at-death
data to obtain an interquartile value (i.e., the difference between
the 75th and 25th percentile data points). Then, 1.53 the inter-
quartile value was added to the 75th percentile data point and sub-
tracted from the 25th percentile data point. Any age-at-death
values outside of this range were identified as potential outliers.
These procedures resulted in a subset of 1,019 subjects (87.5% of
all those with age-at-death data) for a robust analysis of models
that included gender along with both expanded and normal
CAG length (model 1) and only expanded CAG length (model 2),
as summarized in Table 1. In addition, to evaluate the effect of4, 2016
outlier removal, we fitted model 3 to all data without excluding
any samples. We evaluated the model behavior by checking (1) re-
siduals versus fitted values, (2) quantile-quantile plots, and (3) re-
siduals versus leverage (Figure S3).
We also performed three additional tests to establish the robust-
ness of the conclusion from Table 1. (1) Using the minimal
adequate model based on only QC-passed data (Table 1, model 2),
we calculated the residual of age at death for all subjects, including
outlier subjects, with 40–52 CAGs (total of 1,052 subjects) and
subsequently used it as a dependent variable to test the effect of
outliers previously excluded via our QC pipeline (Figure S4).
(2) We compared the distributions of normal CAG length between
HD subjects who represent the top and bottom 10% of residual
age-at-death values (105 individuals each; Figure S5). (3) To deter-
mine the effects of samples excluded from the model because of
repeats longer than 52 CAGs, we constructed an independent
model by using only the 97 HD subjects excluded from the anal-
ysis (Figure S6). None of these additional tests supported any effect
of the normal CAG-repeat length on age at death.Statistical Analysis of Disease Duration
Eight hundred and seventy-eight HD subjects were fully ascer-
tained for both age at motor onset and age at death. For each sub-
ject, we calculated disease duration by subtracting age at onset
from age at death. For these fully ascertained subjects, the range,
mean, SD, and median of duration values were 0–46, 15.4, 6.8,
and 15 years, respectively. Approximately 72.9% of the HD sub-
jects had duration values within 1 SD of themean (8.6–22.2 years),
forming a non-normal distribution with a sharp peak and long
tails, indicating positive excess kurtosis and prompting our non-
parametric statistical analysis. Because duration values of 10–20
years were highly enriched in the data regardless of the length of
expanded CAG repeats, QC analyses that were applied to age-at-
death data and age-at-onset data could not identify a subset of
data points that were normally distributed (Figures S7 and S8).
Therefore, instead of using parametric regression models, we per-
formed non-parametric modeling (i.e., generalized additive model
and Spearman’s rank-correlation analysis) to test the significance
of CAG-repeat lengths and gender on duration. In addition,
we compared disease duration of HD subjects with expanded
CAG < 43 to that of HD subjects with expanded CAG > 45 to
test whether HD subjects with longer expanded CAG repeats
display a shorter duration than do HD subjects with shorter
expanded CAG repeats. In a conceptually similar manner, we
compared expanded CAG-repeat lengths of HD subjects with the
top 10% duration values to those of HD subjects with the bottom
10% of duration values to test whether extreme-duration subjects
vary by expanded CAG-repeat length. Finally, we compared dis-
ease duration of adult-onset HD subjects (age at onset > 20 years)
to that of juvenile-onset HD subjects (age at onset < 21 years)
(Mann-Whitney U test).Survival Analysis of Duration for an Observational
Study Cohort and for Fully Ascertained Samples
In addition to non-parametric duration analyses using HD sub-
jects fully ascertained for both onset and death, survival analysis
was performed with data from the EHDN Registry observational
cohort. In this dataset, 1,314 HD subjects had only a recorded
age at onset, and 115 HD subjects had data on both age at onset
and age at death.We performed a non-parametric survival analysis
using a Cox Proportional Hazards model by setting age at onset asThe Americtime 0 and duration as time to event. For subjects without a re-
corded age at death, age at onset subtracted from age at last study
visit was used as time to event with a censoring indicator. Duration
values were modeled as a function of CAG (continuous variable)
and gender with the ‘‘coxph’’ function in the ‘‘survival’’ R package.
A similar survival analysis approach (but without censoring) using
CAG-repeat size as a continuous predictor variable and gender was
applied to the data for 855 fully ascertained HD subjects used for
our primary non-parametric analysis. In addition, on the basis of
sorted CAG-repeat sizes of fully ascertained samples, two groups
of HD subjects with the top or bottom 10% of extreme CAG re-
peats (85 subjects in each group: 50–63 CAGs or 38–41 CAGs,
respectively) were identified to be compared for duration through
survival analysis.Simulation Analysis
The capacity for CAG length to explain duration was not signifi-
cant in the observed dataset (Figure 3). To estimate whether
different levels of explanatory power of the CAG repeat for dura-
tion could have been visualized in such data, we first randomly
permuted the duration values of the 855 HD subjects. Then,
without data replacement, we sampled duration values randomly
until the model’s R2 value (model: duration ~ CAG) reached 20%,
10%, 5%, 2%, or 1%. Once the model based on permuted data
generated the pre-specified R2 value, the mean duration for each
CAG length based on that simulation set was recorded for plotting
against CAG.Software Package for Statistical Analysis
All statistical analyses were performed with R (version 3.0.2).Results
Age at Death in HD Is Strongly Correlated with the
Length of the Expanded HTT CAG Repeat
We initially compared the relationships between (1)
expanded CAG-repeat length and age at onset of motor
signs, (2) expanded CAG-repeat length and age at death,
and (3) age at onset and age at death. Consistent with pre-
vious findings,6,9,12 analysis using all data points showed
that age at motor onset (Figure 1A) and age at death
(Figure 1B) were both inversely correlated with expanded
CAG-repeat length (adjusted R2 ¼ 65.4% and 74.5%,
respectively). However, a substantial amount of variance
in age at onset and age at death was not explained by the
expanded CAG repeat, suggesting that these outcomes
are modified by other factors. In addition, age at death
was strongly correlated with age at onset (Figure 1C), indi-
cating that the former can be predicted relatively accu-
rately from the latter (adjusted R2 ¼ 77.5%). Interestingly,
the correlation between expanded CAG length and age at
death appeared stronger, given that age at onset is more
variable. This could be because age at onset involves a sub-
jective assessment on the part of an expert clinician,
whereas age at death is objectively recorded. It could also
be that age at onset is more easily modified by other ge-
netic or environmental factors than is age at death. In
any event, the strong correlation between age at deathan Journal of Human Genetics 98, 287–298, February 4, 2016 289
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Figure 1. Correlation between Age at Death and the Length of the Expanded HTT CAG Repeat
(A) Age at onset of motor signs plotted against the expanded CAG-repeat length.
(B) Age at death plotted against the expanded CAG-repeat length.
(C) Age at death plotted against age at onset for individuals for whom both are known.
In each panel, each circle represents a unique HD subject. The red trend line represents a statisticalmodel based on all data points prior to
QC analysis and describes the relationship between natural-log-transformed age at onset and expanded CAG-repeat length (A), between
natural-log-transformed age at death and expanded CAG-repeat length (B), and between age at death and age at onset (C). A summary of
amodel, including its formula, sample number (n), and adjusted R2 (Adj. R2) value is provided inside each plot. The larger variance in age
at onset (A) than in age at death (B) is not due to statistical artifacts related to sample size, given that the R2 values for age-at-onset models
based on randomly picked 1,165 subject sample sets (mean ¼ 0.6537) were similar to those of the original model using all data points.and expanded CAG length indicates that, averaged across
the HD population, the length of the mutation is the pri-
mary factor determining at what age an individual with
HD dies.
Age at Death Is Not Influenced by the Length of the
Normal HTT CAG Repeat
Next, we tested whether variance in age at death in HD is
influenced by the normal CAG repeat or gender. The
expanded CAG repeats in 1,165 HD subjects ranged from
36 to 120 CAGs; the median of the expanded and normal
CAG-repeat lengths was 44 and 18, respectively. We have
reported previously on the importance of conforming to
data-quality assumptions in parametric statistical analysis
of CAG-repeat relationships to avoid spurious results
when testing for potentially subtle effects of modifiers,
and we have proposed a QC pipeline for robust statistical
analysis.12 Among other factors, important requirements
that should be confirmed in parametric regression analysis
include (1) data normality, (2) equal variance, and (3)
absence of disproportionately influential data points. We
performed QC analyses, as described in Lee et al.12 and
in the Material and Methods (Figures S1 and S2), to
generate a dataset that includes 1,019 subjects with 40–
52 CAG repeats and conforms to the assumptions of regres-
sion analysis (Figure S3). We used this dataset to generate
reliable statistical models, model 1 and model 2, which
include and exclude the normal CAG repeat, respectively
(Table 1). Only the expanded CAG-repeat length and
gender explained a significant portion of the variance in
age at death (model 1; adjusted R2 ¼ 66.9%) given that
omitting the normal CAG-repeat length from the model
(model 2; R2 ¼ 66.9%) made no significant difference290 The American Journal of Human Genetics 98, 287–298, February(ANOVA model comparison, p value ¼ 0.1348). Exclusion
of outliers did not change the conclusion given that
model 3, fitted to all data without any sample exclusion,
also revealed significance only for expanded CAG and
gender (Table 1; Figure S3). Similarly, tests involving inclu-
sion of the outliers excluded by the QC pipeline or specific
examination of individuals with >52 CAGs failed to reveal
any significant impact of the normal CAG-repeat length
(Figures S4–S6). Thus, the size of the expanded CAG repeat
and gender have predictive power for age at death, but the
normal CAG length has no discernible impact.
Relationship between Age at Onset and Age at Death:
Disease Duration
The construction of statistical models relating the
expanded CAG repeat length to both age at onset12 and
age at death (Table 1, model 2) allowed us to estimate indi-
rectly the average time between the initial presentation of
diagnostic motor signs and death in male and female HD
subjects. Age at onset was not different between the two
genders (Figure 2A, dashed lines), but there was a signifi-
cant ~1 year difference between males and females in age
at death (Figure 2A, red and blue solid lines). Interestingly,
the age-at-death model (solid) and the age-at-onset model
(dashed) were largely parallel for CAG ranges associated
with onset in adulthood, indicating that the disease dura-
tion from diagnosis to death is similar regardless of
expanded CAG-repeat size. This implies that gender-associ-
ated disease duration is independent of the length of the
expanded CAG repeat, which we have suggested previ-
ously from a limited post-mortem brain study.5,9
We next used several approaches to test this proposition
in the 878 HD subjects for whom disease duration could be4, 2016
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Figure 2. Distribution of Disease Duration by CAG-Repeat Length
(A) Models for age at death (Table 1, model 2) and age at onset12 were constructed with normally distributed samples and a
gender covariate. For the age-at-onset model, gender was included in the model described previously.12 Blue and red lines represent sta-
tistical models for males and females, respectively. Solid and dotted lines represent the CAG age-at-death model and the CAG age-at-
onset model, respectively.
(B) The distribution of disease duration for each expanded CAG repeat was plotted in a boxplot format. Open circles are outliers defined
by a standard interquartile-outlier-identification method. The top, middle, and bottom of the box represent the 75th percentile (upper
quartile), median, and 25th percentile (lower quartile) data points, respectively. The higher and lower whiskers indicate the upper quar-
tile plus 1.53 the interquartile range (IQR) and the lower quartile minus 1.53 the IQR, respectively.measured directly because both age at motor onset and age
at death were ascertained, a much larger dataset than
analyzed previously. The median of the expanded and
normal alleles was 44 and 18 CAGs, respectively. As sug-
gested from the statistical models, although the duration
values were highly variable for any given CAG-repeat
length, the median of measured disease duration for these
HD subjects appeared similar regardless of expanded CAG-
repeat length (Figure 2B). It was not possible to construct a
reliable parametric linear-regression model relating disease
duration and expanded CAG length because the duration
values were not normally distributed; instead, they were
highly enriched with values between 10 and 20 years,
quite different from the distributions of age at onset12
and age at death (Figures S7 and S8). Therefore, as a first
analysis, we instead performed non-parametric statistical
analysis by using a generalized additive model and Spear-
man’s rank correlation, which does not require normal dis-
tribution of the data, to test whether disease duration is
associated with CAG-repeat length. This generalized addi-
tive model based on 855 subjects with those CAG sizes rep-
resented by at least three HD subjects indicated that gender
was a significant predictor of disease duration in that male
HD subjects had a slightly shorter duration than did female
HD subjects (p value ¼ 0.00015). However, there was no
significant association or correlation between disease dura-
tion and either the expanded or normal CAG-repeat length
(Figure 3).
We also specifically examined duration values for HD
subjects with shorter or longer expanded CAG repeats.
The median CAG repeat in our duration data was 44, so
we excluded three consecutive CAGs bins around the me-
dian CAG in order to generate two arbitrary groups of HDThe Americsubjects with (1) similar sample sizes and (2) distinct CAG-
repeat lengths. Disease duration for HD subjects with
expanded CAG length< 43 (Figure S9A, blue; 247 subjects)
and > 45 (Figure S9A, red; 305 subjects) was not sig-
nificantly different (Figure S9B; Mann-Whitney U test,
p value ¼ 0.484). Furthermore, mutant alleles in HD sub-
jects representing the top 10% (Figure S9C, red; median
duration ¼ 27 years; 87 subjects) and bottom 10%
(Figure S9C, blue; median duration ¼ 5 years; 87 subjects)
of duration values showed similar expanded CAG-repeat
sizes (Figure S9D; Mann-Whitney U test, p value ¼
0.8975). Finally, we determined whether duration values
differed between juvenile-onset HD subjects (age at
onset < 21 years old; 55 subjects) and adult-onset HD sub-
jects (age at onset > 20 years old; 823 subjects). This
analysis revealed the expected significant differences in
expanded CAG-repeat lengths, age at onset, and age at
death but no difference in median disease duration be-
tween adult-onset and juvenile-onset HD subjects (Fig-
ure 4D; Mann-Whitney U test, p value ¼ 0.75). In our
data, the mean and median duration of those 11 juve-
nile-onset HD subjects with CAG-repeat size greater than
69 were 9.1 and 9, respectively. Therefore, although disease
duration overall in juvenile-onset HD individuals (age at
onset < 21 years) is similar to that of adult-onset HD sub-
jects, those with extreme juvenile-onset HD (e.g., age at
onset < 10) might have a shorter disease duration.
Consistent with the lack of an effect of the expanded
CAG repeat on disease duration in HD heterozygotes, five
additional HD individuals with two expanded CAG-repeat
alleles had disease duration within 1 SD (8.6–22.2 years) of
the mean. Although this is based on a very small cohort of
‘‘HD homozygote’’ individuals (because of their rarity), itan Journal of Human Genetics 98, 287–298, February 4, 2016 291
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Figure 3. Non-parametric Analyses to Test Effects of CAG-Repeat Size on Duration
(A) Sample sizes were plotted against expanded CAG repeats for statistical modeling of duration.
(B and C) Duration values were plotted against either expanded CAG (B) or normal CAG (C).
(D) A generalized linear model (GAM) was constructed to test the effects expanded CAG, normal CAG, and gender on duration in the
non-normally distributed data. Expanded CAGs with sample sizes greater than 2 (38–63 CAGs) were used. The p values of independent
variables are provided.
(E) In addition, Spearman’s rank-correlation analysis was performed for determining whether duration values correlated with the sizes of
either expanded or normal CAG repeats.suggests further the lack of a dosage effect of mutant HTT
on disease duration.
All of the above comparisons were consistent in support-
ing the conclusion that in HD, disease duration is indepen-
dent of the length of the expanded CAG repeat. Because a
lack of effect of the disease mutation on the duration of
clinical disease is counterintuitive, we were concerned
that an actual correlation with CAG length might be
obscured by some ascertainment bias. There were two sour-
ces of ascertainment for our subjects: (1) cohort studies in
which HD subjects were ascertained for age at onset and in
which a subset of individuals subsequently died and (2)
brain banks where ascertainment was based upon death.
Although our ultimate conclusion was derived from indi-
viduals from both groups where duration could be
measured directly because both parameters were known,
it was conceivable that individuals with shorter CAG-
repeat lengths and potentially longer duration in observa-
tional cohort studies were missed because they have not
yet died. Consequently, we performed a survival analysis292 The American Journal of Human Genetics 98, 287–298, Februaryfor our major source of cohort samples with motor onset:
1,426 heterozygous HD individuals from the EHDN
Registry study. Survival analysis based on this observa-
tional cohort with censoring indications for surviving
HD subjects revealed a significant impact on age at death
for expanded CAG (p value < 2E16), but not normal
CAG (p value ¼ 0.0926). Using non-parametric Cox’s
proportional-hazards analysis, we then tested whether
CAG-repeat length and gender influence survival after
onset. We found no effect on disease duration for either
expanded CAG-repeat length (exponentiated coefficient
per one unit of expanded CAG ¼ 1.007; p value ¼ 0.754)
or gender (exponentiated coefficient for males ¼ 1.178;
p value ¼ 0.385). Tests for proportional-hazards assump-
tion using the ‘‘cox.zph’’ function confirmed that neither
CAG-repeat size nor gender violated the assumption;
p values for expanded CAG length and gender were
0.504 and 0.680, respectively.
A similar analysis of the 10% extremes of CAG-repeat
length from 855 HD subjects from the MA HD Center4, 2016
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Figure 4. HD Subjects with Adult Onset and Juvenile Onset Have Similar Durations
HD subjects with adult age at onset (>20 years; 823 subjects) or juvenile age at onset (<21 years; 55 subjects) were compared for their
expanded CAG repeats (A), age at onset (B), age at death (C), and duration (D) with the Mann-Whitney U test. In each panel, a boxplot
summarizes the distribution of the test object (left), and a summary-statistics table is provided (right).Without Walls collection and for whom both age at onset
and age at death were known showed an influence only of
gender (exponentiated coefficient for low-CAG group ¼
0.8216, p value ¼ 0.22; exponentiated coefficient for
males ¼ 1.2582, p value ¼ 0.146). Survival analysis using
all 855 ascertained subjects and CAG as a continuous var-
iable also revealed no significant contribution of CAG to
duration (p value ¼ 0.665).
Next, we restricted analysis of duration only to those
subjects ascertained through death, i.e., obtained from
HD brain banks. Like the full set of 878 individuals with
a direct measurement of duration, this set of 524 brain-
bank-derived individuals showed no significant correla-
tion between CAG-repeat length and the length of time
between onset and death (Spearman’s rank correlation,
p value ¼ 0.2738; Pearson’s correlation, p value ¼ 0.4529).
Finally, in order to judge the degree to which we had po-
wer to visualize an effect of the expanded CAG-repeat
length on duration, we performed simulation studies based
upon the characteristics of our actual dataset of 855 indi-
viduals of known duration (described in the Figure 3
legend). We simulated distributions of the duration data
across the CAG-repeat range on the basis that CAG-repeat
length explained 1%, 2%, 5%, 10%, or 20% of the variance
in duration (Figure S10). In brief, we used a data matrix of
true CAG-repeat size and duration to calculate R2 to eval-
uate how much variance in duration was explained by
CAG-repeat length in the observed data (Figure S10A).
We then randomly shuffled duration values to obtain
the explanatory power of permuted CAG on duration.The AmericAlthough CAG-repeat length accounted for more than
65% of the variance in age at onset and age at death, it
had no detectable influence on duration (Figure S10A),
whereas these simulations (Figures S10B–S10F) suggest
that even a 2% contribution of CAG-repeat length to deter-
mining duration could have been detected (Figure S10E).
Impact of HTT Haplotypes and a Genetic Modifier of
Age at Onset on Duration
In the absence of an effect of expanded CAG length on HD
duration, we next assessed two additional candidate mod-
ifiers. We first tested whether common HTT haplotypes,
which we have shown do not modify age at onset,27 might
instead have an effect on disease duration.HTT haplotypes
were defined on the basis of 21 common SNPs that show
significant differences in allele frequencies between HD
subjects and normal control individuals.27 ANOVAmodels
in which duration was modeled as a function of HTT
haplotype, either on the disease chromosome (p value ¼
0.363) or on the normal chromosome (p value ¼ 0.091),
provided no evidence of a significant association between
duration and HTT haplotype.
Recently, through a genome-wide association strategy,
we discovered genetic loci significantly associated with
the difference between observed age at onset of motor
signs and that expected on the basis of the CAG-repeat
length of the individual subjects. The genome-wide-signif-
icant locus with the largest effect size, detected by SNP
rs146353869 on chromosome 15, was estimated to accel-
erate motor onset by ~6 years, suggesting hastening ofan Journal of Human Genetics 98, 287–298, February 4, 2016 293
A B C
Figure 5. Duration Is Not Associated with rs146353869
On the basis of recent results from a genome-wide association (GWA) analysis, we tested whether duration is altered by a strong genetic
modifier tagged by SNP rs146353869 on chromosome 15. HD subjects with the minor allele of this SNP developed clinical symptoms
significantly (~6 years) earlier than did subjects with a comparable expanded CAG length but without the minor allele of rs146353869.
(A) Among samples used in our GWA analysis aimed at identifying age-at-onsetmodifiers, 654 individuals had both age-at-onset and age-
at-death data. Disease duration (i.e., age at deathminus age at onset) was plotted against residual age at onset. Gray (636 subjects) and red
(18 subjects) circles represent HD subjects without and with a minor allele for rs146353869, respectively.
(B and C) Residual age at onset (B) and duration (C) of HD subjects without (genotype 0) or with (genotype 1) a minor allele for
rs146353869 are plotted. Black horizontal lines represent the mean. Mann-Whitney U tests were performed to compare residual age
at death (p value ¼ 0.01) and duration (p value ¼ 0.37) between the two groups of HD subjects differentiated by the rs146353869
genotype.HD pathogenesis, at least prior to diagnosis. The same
SNP was significantly associated with age at death cor-
rected for CAG-repeat length (p value ¼ 9.3E5). We
therefore evaluated the potential influence of this strong
age-at-onset modifier locus on disease duration.28 As ex-
pected and shown in Figure 5, HD subjects with a minor
allele for rs146353869 had onset significantly earlier than
those without such an allele (Mann-Whitney U test,
p value ¼ 0.010). However, disease duration was similar
between subjects with and without a rs146353869 minor
allele (Mann-Whitney U test, p value ¼ 0.370). Thus,
the functional variant tagged by rs146353869 modifies
CAG-driven HD pathogenesis but does not influence the
length of the CAG-independent period between onset
and death.Discussion
Our robust statistical analysis based on a large dataset
firmly establishes that, like age at diagnostic onset, the
age at death of HD individuals is determined primarily
by the size of their HTT CAG-expansion mutation and is
not significantly affected by the normal CAG allele.
Indeed, CAG-repeat length is slightly more correlated
with age at death than with age at motor onset because
of greater variance in the latter, which reflects either the
subjectivity of determining onset or its greater susceptibil-294 The American Journal of Human Genetics 98, 287–298, Februaryity to modification. It has been suggested from the effects
of precise genetic replicas of the CAG mutation in the
endogenous mouse ortholog (formerly Hdh, now Htt) and
the fact that these ‘‘knock-in’’ alleles rescue the embryonic
lethality of a null Htt allele that mutant huntingtin might
precipitate pathogenesis by enhancing or dysregulating
some normal activity of huntingtin.29 At least some
normal activities of human huntingtin vary with changes
in CAG length even in the normal size range, revealing the
CAG repeat to be a polymorphism with functional conse-
quences.30 Our data with respect to age at motor onset
and now age at death indicate that any variations in the ac-
tivity of normal huntingtin occasioned by changes in the
size of the normal allele repeat do not have an effect on
the rate of pathogenesis leading to motor onset or death.
Because diagnosis of HD is primarily based upon charac-
teristic motor signs, the length of time that an individual
actually displays HD, i.e., the period between motor onset
and death, is defined here as disease duration. In the liter-
ature, HD disease duration varies greatly (reported ranges
of 1–45 years and medians of 16.2–21.4 years), although
in some cases, analyses have included individuals ascer-
tained for either onset or death, but not both.16,31–33 In
our analyses, we were able to focus on individuals for
whom both age at motor onset and age at death had
been ascertained, permitting a direct assignment of dis-
ease-duration values. Across this dataset, disease duration
(1) is not correlated with the expanded CAG-repeat4, 2016
length, (2) is similar between HD subjects with low and
high CAG expansions, and (3) is comparable between
adult-onset and juvenile-onset HD. In addition, expanded
CAG lengths are similar between HD subjects with shorter
and longer duration. Because our studies were based
exclusively on individuals who have already displayed dis-
ease onset, it remains formally possible that individuals
who have expanded CAG repeats and who are pre-mani-
fest will display a disease duration that is correlated with
CAG-repeat length. However, we think that this theoret-
ical possibility is unlikely. The potential bias of studies
excluding pre-manifest individuals was first considered
in examining the CAG-onset relationship according to a
survival model by Langbehn et al.34 The ‘‘Langbehn
et al. survival model’’ for CAG-onset relationship is similar
to (1) our regression model based on a large cohort of
manifest HD subjects (>4,000) (data not shown) and (2)
predictions from previously published formulae for the
adult-onset CAG-repeat range.35 The similarity between
the two models when the regression-model dataset is large
indicates that the exclusion of pre-manifest individuals
does not substantially bias the estimate of the CAG-onset
relationship. We would expect the same to be true of the
CAG-death relationship and that our duration estimate
based on a large sample of subjects fully ascertained for
both onset and death is not likely to be substantially
biased by the absence of pre-manifest subjects.
Although sometimes assumed, it has not been clearly
demonstrated whether the disease duration of juvenile-
onset HD subjects (<21 years of age) is generally different
from that of adult-onset individuals (>20 years of age).
In one study, disease duration was similar across HD sub-
jects for onset in the juvenile and adult age ranges, and
the duration was somewhat shorter for those with onset
age over 50 years.32 A second report based on age at onset
of first sign and age at death, or on age alone if HD subjects
were still living, noted that extremes of onset, either juve-
nile or elderly, were associated with significantly shorter
durations than typical adult onset.33 Juvenile-onset sub-
jects had a 1- to 2-year-shorter duration (median ¼ 20.0
years) than those with typical adult onset between 20
and 49 years (median of 21.3 years for age at onset between
20 and 34 years; 22.1 years for age at onset between 35 and
49 years).33 The lack of consistency in disease duration
might be due to different definitions and types of onset.
However, breaking down the juvenile-onset category into
only the most extreme cases of individuals who have the
longest CAG repeats and who developed clinical symp-
toms before 10 years of age has been reported to reveal a
significantly shorter disease duration (range ¼ 2–15 years;
mean ¼ 6.6 years) than that of other HD subjects.36,37
Nevertheless, our data indicate strongly that the dura-
tion of the period in which clinical manifestations of HD
are expressed, i.e., the period between diagnosis and death,
is not altered in the vast majority of HD individuals by the
expanded CAG repeat, the normal CAG repeat,HTT haplo-
type, or a strong age-at-onset modifier. Our statisticalThe Americconfirmation of this seemingly counterintuitive finding
argues against the simple scenario in which a toxic CAG-
length-determined property of mutant huntingtin drives
a single pathogenic process that leads in a sequential
manner first to onset and then directly from onset to
death. Rather, it suggests two alternative scenarios for the
HD disease process, and these should be considered in
designing, testing, and interpreting the results of therapeu-
tic interventions, particularly those aimed at silencing the
mutant CAG-expanded HTT allele.
It is well established that the rate of the pathogenic pro-
cess that leads to clinical diagnosis is determined primarily
by the length of the expandedCAG tract. The onset of diag-
nostic motor abnormalities is thought to ensue from the
dysfunction and eventual loss of striatal neurons, and it
has been estimated that at the time of clinical onset, 30%
or more of medium spiny neurons in the striatum have
been lost, and the remainder have already compromised38
by a neurodegenerative process that continues as clinical
manifestations progressively worsen (commonly referred
to as ‘‘progression’’). Indeed, in studies of post-mortem
HDbrains,Hadzi et al. have shown that the extent of striatal
pathology (pathological grade) is correlated both with
CAG-repeat lengthandwithduration.16The formercorrela-
tion is consistent with a CAG-driven pathogenic process
causing striatal pathology. The latter correlation makes
sense because the longer the duration of disease, the longer
that CAG-driven process has to act, and consequently the
greater the extent of striatal pathology. However, we have
shown the lack of correlation between CAG-repeat length
and duration, suggesting that the extent of striatal pathol-
ogyper se is not a determinant of death and that the reasons
for correlation between each of these two parameters and
striatal pathology are distinct. In our analyses of the 310
brains for which pathological grade was known, we found,
like Hadzi et al.,16 that higher pathological grade associates
with longer CAG repeats, earlier onset, and earlier death, all
of which are consistent with a more rapid rate of HD path-
ogenesis with increasing mutation size. The higher patho-
logical grade also associates with longer duration in these
individuals, reinforcing the conclusion that disease dura-
tion is not determined by CAG-repeat length or by the
extent of striatal pathology.
Like motor onset, age at onset of cognitive and, to a
lesser extent, of psychiatric signs is correlated with the
expanded CAG length and might reflect contributions of
additional neuropathological changes in cortical regions.
A simple view of pathogenesis, whereby the same CAG-
driven process in the striatum or in these cortical regions
leads to diagnostic onset and then simply continues with
worsening manifestations and ultimate death, is not a
viable hypothesis because of the CAG independence of dis-
ease duration. Instead, we propose two alternative parsi-
monious explanations for these data.
In the first scenario, the pathogenic process is driven by
mutant huntingtin, and motor onset results when the
coping capacity of the most vulnerable structures,an Journal of Human Genetics 98, 287–298, February 4, 2016 295
particularly the striatum, has reached its limit. Around or
before motor onset, the damage has so weakened the ho-
meostatic mechanisms of the individual that catastrophic
failure of the regions associated with onset enables suscep-
tibility to one or more CAG-independent processes that
contribute to causing early death, on average 15 years later.
In this ‘‘two-stage’’ scenario, CAG-driven pathological
changes, including those affecting other cells and tissues,
and consequent worsening of symptoms continue to occur
after onset, but these CAG-driven changes are not critical to
causingdeath. Instead, death results fromoneormore sepa-
rate CAG-independent processes acting on the background
of a critical juncture reached by the initial CAG-dependent
pathogenesis. The potential CAG-independent processes
that could determine duration are not necessarily limited
to intrinsic biological risk factors, given that many external
factors (nutrition, medical care, nursing-home care, infec-
tious exposure, etc.) could play a contributory role.
In the second scenario, a pathogenic process is driven by
mutant huntingtin independently in multiple cell types in
the brain or in other organs, each of which has a distinct
coping potential. The striatum is most vulnerable and so
succumbs first and produces clinical manifestations that
progress over time. However, neither the occurrence of
diagnostic symptoms nor their progression due to the un-
derlying CAG-length-dependent pathology determines
viability of the individual. Rather, some other cells are crit-
ical for viability, and when these essential cells indepen-
dently reach their coping limit, averaging 15 years after
motor onset, the subject dies. In this second scenario, un-
like the first, a pathogenic process driven by HTT CAG
length leads directly to death in a manner that is not a
downstream consequence of the pathology associated
with characteristic neurological manifestations.
The leading causes of death of HD subjects as reported in
the literature are pneumonia and heart disease.18,39
Although not directly connected to the brain, each of these
causes could occur on the background of physiological
changes occasioned by the neuronal dysfunction that
becomes evident at the time of HD onset (scenario 1) or
could be precipitated by direct effects of mutant hunting-
tin in peripheral cells, such as immune system compo-
nents or cardiac muscle (scenario 2). Indeed, HD subjects
display a number of peripheral abnormalities that could
represent either direct or indirect effects of mutant hun-
tingtin, including abnormal energy metabolism, extreme
weight loss, diabetes, and reduced pulmonary func-
tion.21,23,24,40–42 These all suggest that although HD is clas-
sified as a neurodegenerative disorder, the overall impact of
the HTT CAG expansion is ultimately rather widespread.
Given that HD CAG-driven neuropathological changes in
symptom-associated brain regions continue after onset,
the early mortality in HD might result from effects of the
expanded CAG repeat in vital brain regions not associated
with early clinical symptoms (scenario 2), CAG-repeat ef-
fects outside the brain (scenario 2), or intrinsic or extrinsic
factors unrelated to the CAG repeat (scenario 1).296 The American Journal of Human Genetics 98, 287–298, FebruaryOur findings and the two distinct explanations proposed
for them have implications for developing and testing dis-
ease-modifying therapeutic modalities in HD. Our results
clearly indicate that only the expanded length of the
HTT CAG repeat has significant power for predicting
both age at onset and age at death but that remaining vari-
ance in these measures is unexplained by the CAG muta-
tion and must be due to other causes. One approach that
we and others are taking to reveal validated therapeutic tar-
gets for HD is to identify genetic modifiers of motor onset
in human subjects, i.e., genetic factors that alter the rate of
CAG-driven HD pathogenesis and therefore can identify
target proteins and processes for the development of tradi-
tional small-molecule therapeutics. An example of such a
factor is the as yet undefined functional variant tagged
by SNP rs146353869, which dramatically hastens motor
onset. In both scenarios 1 and 2, drugs based upon modi-
fication of CAG-driven processes would be expected to be
effective in delaying both onset and death if they are deliv-
ered sufficiently prior to onset. In scenario 2, such inter-
ventions might also be expected to delay death even if
they are delivered after motor onset, whereas in scenario 1
they might alleviate the progression of clinical symptoms
without actually delaying death. The CAG independence
of disease duration suggests that if the first scenario is cor-
rect, an array of modifiers and potential therapeutic targets
different from those involved in CAG-dependent processes
might be effective in delaying death. Indeed, both alterna-
tive scenarios also allow for modifiers that act in a cell- or
tissue-specific fashion and have the potential to modify
predominantly age at onset or disease duration, but most
likely not both.
A fundamentally different route to therapeutic interven-
tion currently being explored is suppression of mutant
huntingtin expression through nucleic-acid-based gene-
silencing strategies. Planning for initial clinical trials has
typically considered delivery of the therapeutic agent to
the brains of HD individuals early after clinical diagnosis
with the goal of delaying the progression of clinical symp-
toms and associated neuropathology. In our first scenario,
such treatment can be very effective in limiting the pro-
gression of clinical symptoms and improving quality of
life without necessarily altering disease duration given
that the latter is independent of CAG-repeat length.
Consequently, although it presents greater regulatory hur-
dles and difficulties in clinical-trial design, the ideal time to
treat with a HTT-suppression strategy is significantly prior
to diagnostic onset because an effective treatment would
then be expected to delay both onset and death. In the sec-
ond scenario, treatment of the brainmight have no impact
on preventing death if the gene-silencing strategy is not
being delivered to the cells or organ responsible for main-
taining viability. Thus, in either scenario, our findings sug-
gest that a brainHTT-silencing strategy that is successful in
reducing the progression of symptoms might improve the
quality of life of HD individuals without necessarily pre-
venting their early death.4, 2016
Although it is not currently possible to distinguish be-
tween our two scenarios for HD pathogenesis leading to
early death, theCAG independence of disease duration sug-
gests that the results of treatment trials measuring some as-
pects of clinical progression after onsetmight not be predic-
tive for the efficacy of the same treatments in preventing
motor onset or early death. Fortunately, ongoing large nat-
ural-history studies of HD offer a route for more fully
exploring the biological basis of early death in HD in order
to distinguish between these explanations and to guide
therapeutic development. Most importantly, the applica-
tion of the continuous CAG analysis strategy, applied
here to onset and death, to defining and distinguishing
other phenotypic measures (molecular, imaging, neurolog-
ical, etc.) tied to the pathogenic process offers the hope of
enabling clinical trials before motor onset, when disease-
modifying treatments based upon CAG-length-dependent
effects are expected to be most broadly effective.Supplemental Data
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